Compares sonrotoclax with venetoclax in adults with returned chronic lymphocytic leukemia
Tests sonrotoclax with antibody treatment in adults whose chronic lymphocytic leukemia has returned.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Key facts
- Where
- Aurora, Baltimore, Baton Rouge, Boston, Chapel Hill, Charlotte, Chattanooga, Chicago, Cincinnati, Dallas, Eugene, Grand Rapids, Hershey, Iowa City, Laguna Hills, Louisville, Nashville, New Haven, New York, Niles, Norwich, Omaha, Orange, Palo Alto, Philadelphia, Pittsburgh, Rochester, San Antonio, San Diego, Santa Fe, Seattle, Sewell, Tyler, Vancouver, Waukee, Westbury, Weston, and Winston-Salem, United StatesSee the 39 sites
- Phase
- Phase 3
Where in United States
- Rocky Mountain Cancer Centers (Williams) - USORAurora, United StatesTaking people
- The University of Maryland Greenebaum Comprehensive Cancer CenterBaltimore, United StatesTaking people
- Mary Bird Perkins Cancer CenterBaton Rouge, United StatesTaking people
- Beth Israel Deaconess Medical Center (BIDMC)Boston, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- University of North Carolina at Chapel HillChapel Hill, United StatesTaking people
- Levine Cancer CenterCharlotte, United StatesTaking people
- Tennessee Oncology Greco Hainsworth Centers For Research ChattanoogaChattanooga, United StatesTaking people
- Northwestern UniversityChicago, United StatesTaking people
- Oncology Hematology Care Clinical Trials LLCCincinnati, United StatesTaking people
- Texas Oncology - Baylor Charles A. Sammons Cancer CenterDallas, United StatesTaking people
- Oncology Associates of Oregon Willamette Valley Cancer CenterEugene, United StatesTaking people
- The Cancer and Hematology CentersGrand Rapids, United StatesTaking people
- Penn State Milton S. Hershey Medical CenterHershey, United StatesTaking people
- University of Iowa Hospitals and ClinicsIowa City, United StatesTaking people
- UCI Health - Laguna HillsLaguna Hills, United StatesTaking people
- University of Louisville Brown Cancer CenterLouisville, United StatesTaking people
- Tennessee OncologyNashville, United StatesTaking people
- Yale University, Yale Cancer CenterNew Haven, United StatesTaking people
- Memorial Sloan Kettering Cancer Center MskccNew York, United StatesTaking people
- Illinois Cancer Specialists (Niles) UsorNiles, United StatesTaking people
- Eastern Connecticut Hematology and OncologyNorwich, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- Chao Family Comprehensive Cancer CenterOrange, United StatesTaking people
- Stanford Cancer InstitutePalo Alto, United StatesTaking people
- Thomas Jefferson UniversityPhiladelphia, United StatesTaking people
- Upmc Hillman Cancer Center(Univ of Pittsburgh)Pittsburgh, United StatesTaking people
- Mayo Clinic - RochesterRochester, United StatesTaking people
- Texas Oncology - San Antonio Medical Center - USORSan Antonio, United StatesTaking people
- Scripps Prebys Cancer CenterSan Diego, United StatesTaking people
- CHRISTUS St. Vincent Regional Cancer CenterSanta Fe, United StatesTaking people
- Swedish Medical Center Swedish Cancer Institute First Hill CampusSeattle, United StatesTaking people
- Sidney Kimmel Comprehensive Cancer Center Washington TwpSewell, United StatesTaking people
- Texas Oncology - TylerTyler, United StatesTaking people
- Northwest Cancer Specialist, Pc(Us Oncology Research)Vancouver, United StatesTaking people
- Mission Cancer and BloodWaukee, United StatesTaking people
- Optum Medical Care, PCWestbury, United StatesTaking people
- Cleveland Clinic FloridaWeston, United StatesTaking people
- Atrium Health Wake Forest BaptistWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BeOne Medicines
- Trial code
- NCT06943872EU 2024-517131-52-00
- Record updated
- 23 October 2026
- Original description
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.Read full original descriptionShow less
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Inclusion: Confirmed diagnosis of CLL/SLL that meets the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria; Received one or more prior therapies for CLL/SLL. For each line of therapy, participants must have received at least 2 cycles of the therapy; Participants with prior BCL2i exposure are eligible if remission duration was ≥3 years with ≥2 years from last BCL2i intake; Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2; Adequate organ function.
Exclusion: Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug; Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent; Severe or debilitating pulmonary disease; Clinically significant cardiovascular disease; NOTE: Other protocol defined Inclusion/Exclusion criteria may apply; Known active prolymphocytic leukemia or currently suspected Richter's transformation; Known central nervous system involvement by CLL/SLL.